The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
H Watz, P Calverley, P Chanez, R Dahl, M Decramer, B Disse, H Finnigan, AM Kirsten, R Rodriguez-Roisin, K Tetzlaff, L Towse, E Wouters, H Magnussen · Pneumologie · 2015 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: WISDOM (NCT00975195) demonstrated non-inferiority in exacerbation risk with ICS withdrawal versus ICS (ERS 2014). Here we report the change in lung function. Objective: To evaluate the effects of stepwise withdrawal of ICS in patients (pts) with GOLD 3 – 4 COPD and a history of exacerbation treated with LAMA+LABA. Methods: WISDOM was a 12-month, double-blind, parallel-group, active-controlled study where all pts received triple therapy (tiotropium 18 µg QD, salmeterol 50 µg BID and fluticasone 500 µg BID) for a 6-week run-in period. Pts were randomised 1:1 to continue triple therapy or stepwise withd…
